Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant ITGA4, ITGB7 (Abrilumab Biosimilar) antibody

This Human Monoclonal antibody specifically detects ITGA4, ITGB7 (Abrilumab Biosimilar) . It exhibits reactivity toward Human.
Catalog No. ABIN7597488
-15% Promotion 2026
$340.97
$401.14
save $60.17 (-15 %)
Plus shipping costs $50.00, if applicable $20.00 dry ice
Shipping to: United States
Delivery in 12 to 14 Business Days

Quick Overview for Recombinant ITGA4, ITGB7 (Abrilumab Biosimilar) antibody (ABIN7597488)

Target

ITGA4, ITGB7 (Abrilumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
Human

Clonality

  • 1
Monoclonal

Conjugate

  • 1
This ITGA4, ITGB7 (Abrilumab Biosimilar) antibody is un-conjugated

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Research Grade Abrilumab Biosimilar Antibody

    Specificity

    ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4, Gut homing receptor beta subunit, Integrin beta-7, ITGB7

    Purification

    Protein A or G purified from cell culture supernatant.

    Purity

    >95 % by SDS-PAGE.

    Isotype

    IgG2 kappa
  • Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    1 mg/mL

    Buffer

    0.01M PBS, pH 7.4.

    Storage

    4 °C,-20 °C,-80 °C

    Storage Comment

    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

    Expiry Date

    12 months
  • Target

    ITGA4, ITGB7 (Abrilumab Biosimilar)

    Alternative Name

    Abrilumab Biosimilar

    Target Type

    Biosimilar

    Background

    ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4, Gut homing receptor beta subunit, Integrin beta-7, ITGB7

    UniProt

    P13612, P26010

    CAS-No

    1342290-43-0
You are here:
Chat with us!